

Expert Opinion

1. Introduction
2. Properties of PEG
3. Designing PEG conjugates
4. Routes of administration
5. POLY PEG® and oral delivery of salmon calcitonin
6. Improvement of other delivery technologies by PEGylation
7. siRNA delivery and PEG
8. Conclusion
9. Expert opinion

informa
healthcare

Advances in PEGylation of important biotech molecules: delivery aspects

Sinéad M Ryan, Giuseppe Mantovani, Xuexuan Wang, David M Haddleton & David J Brayden[†]

[†]*University College Dublin, School of Agriculture, Food Science and Veterinary Medicine, Belfield, Dublin 4, Ireland*

Background: Although various injected peptide and protein therapeutics have been developed successfully over the past 25 years, several pharmacokinetic and immunological challenges are still encountered that can limit the efficacy of both novel and established biotech molecules. **Objective and method:** PEGylation is a popular technique to address such properties. PEGylated drugs exhibit prolonged half-life, higher stability, water solubility, lower immunogenicity and antigenicity, as well as potential for specific cell targeting. Although PEGylated drug conjugates have been on the market for many years, the technology has steadily developed in respect of site-specific chemistry, chain length, molecular weights and purity of conjugate. These developments have occurred in parallel to improvements in physico-chemical methods of characterization. **Conclusion:** This review will discuss recent achievements in PEGylation processes with an emphasis on novel PEG-drugs constructs, the unrealized potential of PEGylation for non-injected routes of delivery, and also on PEGylated versions of polymeric nanoparticles, including dendrimers and liposomes.

Keywords: drug delivery, PAMAM dendrimers, PEG, PEGylation, PEGylated liposomes

Expert Opin. Drug Deliv. (2008) 5(4):371-383

1. Introduction

Biotechnology produces important novel recombinant molecules that are able to mimic endogenous hormones, cytokines and antibodies [1]. One of the major hurdles has been the difficulty in synthesizing sufficient quantities for subsequent testing. However, due to more efficient genetic engineering, recombinant polypeptides can now be produced in relatively large quantities at a much lower cost than before. Despite this, inadequate delivery is a barrier to the effective administration of many promising biotech molecules. Parenterally administered proteins tend to be either cleared from circulation by the reticuloendothelial system (kidney, spleen, liver) or metabolized by serum peptidases leading to loss of biological activity. Oral delivery is more problematic than the parental route, as protein-based therapeutics are rapidly destroyed by the digestive system and are poorly absorbed across the small intestinal epithelium [2].

Many approaches have been explored to enhance parenteral polypeptide delivery. These include the alteration of amino acid sequences to reduce degradation by serum and liver enzymes and to reduce antigenic side effects. Peptides can also be fused to immunoglobulin or albumin to increase half-life [3] and, in addition, they can be entrapped in insoluble matrices and immobilized on to polymer resins for use with extracorporeal shunts. By far the most successful approach is the covalent coupling of PEG chains to the molecule (PEGylation) [4-6]. Important pioneering work was performed by

Davis and Abuchowski in the late 1970s [7,8]. Site-specific PEGylation modifies many peptide features to reduce clearance, although biological functions of the peptide can be compromised by reducing access to receptors [9]. PEGylation has been shown to increase drug efficacy and this has been attributed to a combination of increased molecular size [10,11] (which reduces glomerular filtration) and masking of the protein surface (which decreases immuno-recognition response and proteolytic degradation) [10,12]. A typical example of this balanced benefit is PEGylated interferon α -2a (Pegasys®, Roche, USA), which retains only 7% of the antiviral activity of the native protein, but still shows a greatly improved pharmacokinetic performance following weekly injections *in vivo* in hepatitis C patients, compared with the unmodified enzyme [13]. PEG also confers new physicochemical properties and can modify both biodistribution and solubility [14]. Due to these favorable properties, PEGylation plays an important role in parenteral drug delivery, enhancing the potential of peptides and proteins as therapeutic agents. Even though several attempts have been made to develop new polymers that can also confer improved pharmacokinetics on conjugated peptides (e.g., polysialylation; Lipoxen, UK) [15], it remains to be seen whether these approaches can compete with PEGylation in terms of better efficacy, reduced numbers of injections, adequate biocompatibility and versatility in polymer design. While progress in PEGylation for injectables has led to many marketed biotech products, its use in oral and pulmonary delivery formats is only just beginning to be explored.

2. Properties of PEG

PEGylation usually employs functionalized mono-methoxy PEG (mPEG) molecules to covalently attach to surface-available groups on the protein, most commonly through multi-site binding to the ϵ -amino group of lysine residues or through site-specific binding to free cysteine residues or via protein engineering [16]. PEG is a linear polyether diol, with the chemical formula $\text{HO}-(\text{CH}_2\text{CH}_2\text{O})_n-\text{H}$. It can be made in various molecular weights and functionalized architectures (e.g., amino-, carboxyl- and sulfhydryl-terminated). Low molecular weight (< 500 Da) PEGs are viscous, colorless liquids, whereas higher molecular weight PEGs are waxy solids due to crystallization whose melting points increase towards an upper limit of 70°C [17]. PEGs are hydrophilic and dissolve in most solvents including methanol, benzene, dichloromethane and water; they are insoluble in saturate hydrocarbons. PEGs are also eliminated by a combination of renal [18] and hepatic pathways [19,20], their simple elimination pathways making them useful in pharmaceutical applications. PEG has the lowest level of protein or cellular adsorption of any known polymer; it is non-toxic, non-immunogenic, non-antigenic and has been FDA-approved for many injected biotech products. The first examples of

PEG-protein drugs were commercialized in the early 1990s (Table 1) and since then a number of clinical trials involving polymer-drug conjugates have shown promising results.

The technique of PEGylation has expanded to include a wide range of chemical and enzymatic conjugation methods [21,22]. This variety offers the possibility to address specific requirements of different proteins. The choice of appropriately end-functionalized PEG allows the modification of only the desired amino acids in the sequence. Amino groups were the first target of PEGylation, by acylation or alkylation reactions [23], but now conjugation of PEG to thiol or hydroxyl groups and to disulfide bridges has also been made possible by using several specific chemical or enzymatic methods. A number of authors have provided thorough reviews of novel PEGylation chemistry [16,24].

3. Designing PEG conjugates

Polymeric conjugates must be carefully designed for their individual use, taking into account the nature of the individual drug payload and the location of each molecular pharmacological target. Typical PEG conjugates contain the polymer, a linker and the bioactive agent. The following are important points to consider:

- The molecular mass and physico-chemical properties of the polymer [25,26] are frequently the most important drivers governing biodistribution, elimination and metabolism of the conjugate, therefore the choice of a suitable PEG is important.
- The water-soluble biocompatible polymeric carrier must be suitable for repeated administration. PEG polymers have been typically limited to < 30 kDa in relation to their viscosity radius in order to ensure eventual glomerular elimination [10]. However, there is a debate regarding this issue. For example, comb-shaped PEGs can have a different viscosity radius compared to linear PEGs of the same molecular weight [10].
- In the case of non-biodegradable high molecular weight polymers, the linker to the molecule is an important design feature. The *in vivo* protein stability of most polypeptides is limited and therefore needs to be attached to a polymer of high molecular weight. However, PEGylation of high molecular weight non-biodegradable polymers can alter the structure of the drug and reduce bioactivity when compared to the original protein. Drug-polymer conjugates or complexes need to be stable in the blood prior to the drug being liberated at the site of action. In principle, the polymer-bound drug can be released by non-specific hydrolysis by enzymes, by reduction, or by pH-dependent metabolism. Tissue-specific expression of enzymes and altered local pH, as well as cellular endocytotic pathways, offer several options for designing conjugates that can be preferentially cleaved at the preferred site of delivery. For example, the microenvironment of tumors can be

Table 1. PEG-conjugates: marketed and different stages of development.

PEG conjugates	Name (Company)	PEGylation	Status	Disease
1-asparaginase [109]	Oncaspar® (Enzon)	Multiple linear PEGs 5 kDa	Market, 1994	Acute lymphoblastic leukemia
Adenosine deaminase [110]	Adagen® (Enzon)	Multiple, linear PEGs 5 kDa	Market, 1990	Severe combined immunodeficiency disease (SCID)
Growth hormone receptor antagonist [111]	Somavert® (Pfizer Pharmacia)	4–6 linear 5 kDa PEG chains per protein molecule	Market, 2002	Acromegaly
Zn-protoporphyrin (ZnPP) [112]	Patent	Random, linear PEG 5 kDa	Pre-clinical	Suppression of bilirubin
Alsterpaullone [113]	Alsterpaullone (A.G. Scientific Inc.)	40 kDa urea linked	Pre-clinical	Treatment of Alzheimer's disease
PEG-anti-TNF Fab [114]	CDP870, Cimzia® UCB (formerly Celltech)	Not available	Market, 2008	Rheumatoid arthritis and Crohn's disease
Interferon α 2a [114]	Pegasys® (Roche Pharmaceuticals)	Random, branched with two 20 kDa PEG chains	Market, 2002	Hepatitis C
Interferon α 2b [115]	PEG-Intron® (Schering-Plough)	Random, linear PEG 12 kDa	Market, 2000	Hepatitis C, cancer, multiple sclerosis, HIV/AIDS
G-CSF (PEG-filgrastim) [116]	Neulasta™ (Amgen)	20 kD PEG is bound to N-terminal methionyl residue of Filgrastim	Market 2002	Prevent severe cancer chemotherapy-induced neutropenia
Insulin (CaP-polyethylene glycol (PEG)-insulin nanoparticles) [65]	BioAir™ (BioSante Pharmaceuticals)	Not available	Pre-clinical	Diabetes
Branched PEG-anti-VEGF aptamer (Pegaptanib, Macugen™) [117]	Pegaptanib, Macugen™ (OSI Pharmaceutical/Pfizer UCB)	Selective, 40 kDa branched PEG, each branch 20 kDa	Market, 2004	Macular degeneration (age-related)

acidic in both animal models and human patients [27]. Low pH in endosomes and lysosomes, as well as the presence of lysosomal enzymes present in tumor cells, can therefore be exploited for releasing the drugs bound to polymers through acid-sensitive linkers [28]. For the purpose of this review, polymer–protein hybrids have been divided in three groups based on the macromolecular architecture of the conjugating polymers (Figure 1A – C).

3.1 Linear PEGylating reagents

One or more linear PEG chains with a medium-to-high molecular weight between 1 and 40 kDa are bound to the surface of the protein (Figure 1A). Suitable PEGylating agents are typically prepared by chemical modification of the PEG terminal hydroxyl moieties [23,29]. With notable exceptions [30,31], synthetic routes in the early years of the PEGylation era lacked the capacity to produce pure mono-functional PEG derivatives of high molecular weight. Since the diol content of high molecular weight PEGs could be as high as 15%, first-generation PEG chemistry tended to be inefficient for protein conjugation due to the inevitable presence of cross-linked conjugates. Another drawback of

such early PEGylation agents was the lack of site-specificity in the conjugation step, which typically led to a heterogeneous mixture of regioisomers. Despite this, several first-generation candidates received regulatory approval due to their superior and reproducible efficacy over the parent molecules. PEGylated granulocyte colony stimulating factor (PEG-G-CSF) (Neulasta®, Pegfilgrastim, Amgen, USA) was conjugated with a 20-kDa linear PEG chain and was approved in 2002. This treatment is more convenient than injections of human recombinant G-CSF (Neupogen®, Filgrastim, Amgen, USA), since only one injection of Neulasta is required every three weeks compared to daily injections of Neupogen over two weeks [32]. Similarly, Pegasys®, using a 40-kDa PEG chain, is a competitor of the first-generation conjugate of interferon α 2b, PEG-Intron® (Schering, USA). Both PEG-Intron and Pegasys have shown improved efficacy in the treatment of hepatitis C over native interferon, especially when combined with the antiviral agent ribavirin [33].

At present, PEGylation to free cysteine residues probably remains the most efficacious strategy for site-specific conjugation, mainly using maleimide- or




Figure 1. Polymer-protein hybrid therapeutics divided into three groups based on the macromolecular architecture of the conjugating polymers. A. Linear PEGylating reagents. B. Y-shaped PEGylating reagents. C. Highly branched PEGylating reagents.

2-pyridyl disulfide-terminated conjugating polymers (Table 2). Free cysteine residues are rather rare in native (poly)peptides and often they need to be introduced via protein engineering. Preferential targeting of N-terminus have been achieved by reductive amination using aldehyde-terminated PEGylating agents that are able to react with protein primary amine fragments to form Schiff bases that can be then reduced *in situ* to give hydrolytically stable secondary amines. It was found that at a relatively low pH (typically < 6), most of the ϵ -amino group of lysine residues are protonated, while the N-terminus nitrogen atoms remain relatively non-protonated and are able to react with aldehyde-functional PEGylating agents. Recently, Brocchini and coworkers [34–37] introduced an elegant strategy in which disulfide bridges are first reduced, then reacted with methoxy PEGs bearing a bi-functional reacting agent at the chain end. Bis-alkylation of the resulting free thiols gave a three-carbon bridge to which PEG was covalently attached (Table 2).

3.2 Y-shaped PEGylating reagents















Functional Y-shaped PEGs (Figure 1B) have received growing interest [38–42] due to some reports indicating improved biological efficacy compared to the analogous therapeutics in which a linear conjugating PEG was used. The macromolecular structure of the conjugating polymer has proven to be crucial for the improved properties of the corresponding bio-conjugates. Compared to linear PEG, branched PEGs

can further reduce resistance to proteolysis and reduce immunogenicity, and this is thought to be in part due to their umbrella-like shape [24].

3.3 Highly branched PEGylating reagents

Comb-shaped polymers with one specific site of attachment represent a new type of PEGylation agent. One such polymer is POLY PEG[®], where PEG ‘teeth’ are linked to a methacrylate backbone via an ester bond (Figure 1C). POLY PEG has more degrees of freedom than linear PEG, enabling structure optimization. Conventional PEGylation agents are prepared by ring opening polymerization of ethylene oxide, usually initiated by an alkoxide derived from an appropriate alcohol. Depending on the synthetic route selected, subsequent chemical transformations result in the desired PEG for conjugation. This living ring opening polymerization is complicated by the inevitable presence of trace water/protic species which offer a competing initiating pathway resulting in a hydroxyl end group on the initiating end of the chain as well as the terminating end. In addition, multiple chemical transformations are often required to obtain the desired conjugating functionality. Since it is not possible to either have a 100% chemical yield or to separate polymers which differ only in their end group functionality, the resulting PEG is always a mixture of desired conjugating agent and impurities. These complications escalate as the molecular weight of the polymer is increased, as is required for single-site attachment, due to inherent problems with

Table 2. Examples of site selective conjugation of proteins to PEG.

Conjugation site (R = protein)	Reactive polymer chain-end	Protein (R) conjugate
Primary amines, R-NH ₂ (lysine, N-terminus)	 NHS esters	
	 NHS carbonates	
	 Aliphatic aldehydes	 (After <i>in situ</i> reduction)
Thiols, R-SH (cysteine)	 Maleimide	
	 Pyridyl disulfides	
	 Vinyl sulfones	
		

living ring opening polymerization of epoxides. The new generation of polymers are prepared by Transition Metal-Mediated Living Radical Polymerization (TMM-LRP, often called ATRP), a technique that allows tight control over the polymer molecular weight and over macromolecular architecture when compared to other polymerization chemistry [43,44]. The PEG is present in the form of commercially available (meth)acrylic monomers of different molecular weights. The polymer has an (meth)acrylic backbone with PEG teeth and one functional group per polymer. The quantity of PEG can be varied by altering the length of the PEG teeth using different PEG methacrylate monomers of varying molecular weight (typically 0.5 – 2 kDa). Similarly, the length of the methacrylate backbone can be altered, allowing the molecular weight to be varied in two dimensions by changing the [monomer]/[initiator]. A toothless spacer segment can also be inserted to keep the 'comb' further away from the protein. Thus, polymers can be tailored to incorporate active end-groups for specific amino acid targeting. For example, POLY PEG allows conjugation through a number of active targeted end-groups such as aldehyde, succinimidyl ester and maleimide, which react with the *N*-terminus amine, lysine and cysteine units respectively [45,43,46].

Linear PEG normally has one hydroxyl end-group which can be chemically converted into a different functionality to enable conjugation. It is possible for some chains to have functionality at both ends, which could lead to undesirable cross-linked protein-polymer biohybrid materials. In contrast to linear PEG, the living radical polymerization method used to synthesize comb polymers ensures that each polymer molecule is limited to a single terminal conjugating group [47]. Ongoing studies are examining whether these hybrid comb polymer conjugates have improved pharmacokinetics, reduced immunogenicity, reduced toxicity and a longer plasma half-life compared to parent protein and other PEGylated formats. However, there is still the issue of the degradation of these 'comb' polymers and the release of the peptide attached. POLY PEG has ester bonds connecting the PEG teeth to the methacrylate backbone, which should break when they come into contact with protease enzymes, and this is the subject of ongoing studies. Importantly, incorporation of a labile linker between the peptide and other PEG polymers has been achieved [48] and this technology could be applied to comb polymers such as POLY PEG®.

Other comb polymers with acrylic backbones are also under investigation such as the pH-sensitive poly[2-(diethylamino)ethyl methacrylate] (PDMAEMA) backbone modified with poly(L-lysine) (PL) side chains, which has potential to be used as a DNA carrier. Although not a PEGylating agent, this polymer has unique properties in that it is responsive to pH in solution [49]. A continuation of this work has seen the synthesis of comb-type copolymers consisting of a PL main

chain, a DNA binding site, hyaluronic acid (HA) side chains and cell-specific ligands [47]. By using the PL-graft-HA comb-type copolymers, it may be possible to control the properties of the DNA complex such as complex size, solubility and the degree of DNA compaction. Both of these comb-type copolymers might be used to increase the efficiency of cell targeting for siRNA cytosolic delivery. In another example, Srividhya *et al.* [50] synthesized an amphiphilic comb polymer with PEG attached to poly(dimethyl siloxanes) (PDMS-PEG) via hydrosilylation with reactive epoxy groups for protein attachment. Thin membranes loaded with BSA were prepared and attached to PDMS-PEG and the release profile was continuous and controlled over 72 h. Thermo-responsive poly(*N*-isopropylacrylamide) poly(NIPAM), has also been conjugated to streptavidin, allowing for thermal release at body temperature *in vivo* [51,52]. Conjugates have also been used to produce self assembly into giant amphiphiles and to combine multiple properties along the backbone of the polymer when conjugated to BSA [53].

4. Routes of administration

Since biopharmaceuticals are now approaching 50% of all new drugs in development, there is considerable interest in non-injected delivery to improve patient acceptability [54]. Gene and siRNA delivery have additional barriers to negotiate over those of peptides, namely intracellular escape from lysosomal decay, as well as intact delivery to either nuclear DNA or to cytoplasmic RNA. Incorporation of PEGylation concepts are being researched in order to overcome these different type of delivery barriers [55].

While oral delivery remains the preferred option for peptides, increasing interest in pulmonary delivery also indicates the potential of that route for the delivery of biopharmaceuticals [56]. Inhalation is the fastest delivery system (apart from intravenous injections) for small peptides due to the large surface area of the lungs, good epithelial permeability and the highly dispersed nature of the aerosol. An inhaled dry powder aerosol of insulin (Exubera®) was developed by Nektar and marketed by Pfizer in 2006. Although the delivery of inhaled insulin matched that of subcutaneous delivery, it was recently withdrawn due to poor sales, just a fraction of the total insulin market. While the reasons for failure are many, there was patient perception of long-term pulmonary safety issues, in addition to acceptability issues with the device [57]. Recently, Novo Nordisk also halted development of Aradigm's AERx® inhaled insulin system which was in Phase III trials. However, there are a number of other fast-following inhaled insulin particle systems at late stages of development from Alkermes/Lilly (AIR® Insulin) and MannKind (Technosphere® Insulin System) [58-62], perhaps indicating that there is potential to improve upon the first inhaled insulin by using different types of particles, delivery devices




Figure 2. Concentration response curves of sCT and sCT-POLY PEG® (Mw of conjugate is 9.5 kDa) for the stimulation of cAMP secretion in the breast cancer cell line T47D. A comparison of EC_{50} values for sCT and sCT-POLY PEG® was 135 ± 19 and 197 ± 31 pM respectively. Conjugation of POLY PEG® onto sCT therefore does not inhibit bioactivity.

and excipients. PEGylation can also promote pulmonary delivery to achieve longer-lasting peptide effects [63,64].

BioAir™ (Biosante Pharma, USA) comprises calcium phosphate nanoparticulates (CaP) of insulin, and CaP-PEG particles significantly reduced the elimination of insulin in rats following pulmonary administration. Consequently, the amount of bioavailable insulin from this pulmonary formulation was also equivalent to or higher than that of insulin injected subcutaneously [65]. For the potential treatment of lung cancer, transferrin-conjugated liposomes were PEGylated and tested for inhalation following nebulization [66,67]. These PEGylated targeted liposomes showed more stability and retained > 80% of their drug load over 48 h. This was sufficient time for the drug carriers to be taken up by cancer cells over-expressing transferrin receptors in the lung.

5. POLY PEG® and oral delivery of salmon calcitonin

Injected and nasal salmon calcitonin (sCT) is used for the treatment of osteoporosis and Paget's disease, but upon oral delivery it is subject to proteolytic attack by intestinal peptidase enzymes and demonstrates poor intestinal epithelial permeability [68]. Nasally administered sCT (Miacalcin®, Novartis, Switzerland) displays variable absorption and there is local cytotoxicity over time [69]. In addition, although the osteoporosis market is now dominated by long-acting oral bisphosphonates, these drugs have stringent administration requirements and are associated with patient perception of limited efficacy and side effects [70]. There is substantial interest in developing an oral formulation of sCT and current approaches include conjugation to alkyl-PEG [10] and PEGylated chitosan nanoparticles [4]. Site-specific conjugation of linear PEG to Lys¹⁸-amine (Lys¹⁸-PEG_{2K}-sCT) has been achieved [71] and also of comb-shaped POLY PEG® to Cys¹ in our own research.

A comparison of EC_{50} values was calculated from concentration-response curves comparing the bioactivity of sCT to sCT-POLY PEG®. The intracellular cyclic AMP values achieved in a breast cancer cell line over-expressing calcitonin receptors were 135 ± 19 and 197 ± 31 pM for sCT and sCT-POLY PEG respectively (Figure 2). The conjugate also significantly improved the resistance of sCT to intestinal peptidases at relevant concentrations of enzymes (Figure 3) and prolonged the half-life of sCT *in vivo* over the sCT following intravenous injection (Figure 4). POLY PEG has also been successfully used to PEGylate lysozyme [45,72] and BSA [46] to create conjugates that are also bioactive *in vivo*.

6. Improvement of other delivery technologies by PEGylation

6.1 Polyamidoamine (PAMAM) dendrimers

PAMAM dendrimers consist of a central core, branching units and terminal functional groups and they were the first complete dendrimer family to be synthesized, characterized and commercialized [73,74]. They have attracted great attention for potential in biomedical applications [75-77] and are commercially available macromolecules that can be used as carriers for plasmid DNA, antisense oligonucleotides [78-80] and siRNA [81-83]. Although the PAMAM dendrimer has already been tested as a carrier for drug and gene delivery, there are potential problems with regard to payload solubility and cytotoxicity. Cytotoxicity of PAMAM dendrimers increases with generation (G), independent of surface charge, for both full generation cationic dendrimers (G2 – G4) and the “half-generation” anionic intermediates (G2.5, G3.5). A partial derivatization with four PEG chains on a G4-PAMAM, respectively, was sufficient to lower cytotoxicity [84,85].

Many workers have examined the usefulness of PEGylated dendrimers to enhance drug solubility. Bhadra *et al.* devised




Figure 3. Stability of sCT-POLY PEG® (Mw of conjugate is 9.5 kDa) and sCT when incubated with the intestinal enzyme trypsin at the gastro-intestinal concentration (50 µM). sCT-POLY PEG® has significantly increased resistance to the peptidase enzyme trypsin, compared to free sCT which is degraded at 30 min. Samples were analysed by SEC-HPLC.




Figure 4. sCT in rat serum after i.v. administration of sCT and sCT-POLY PEG® (Mw of conjugate is 40 kDa) in rats (n = 3 – 5). Serum samples were obtained before sCT/sCT-POLY PEG® were injected and at time intervals afterwards. sCT was measured by ELISA.

PEGylated 'nanocontainers' using G4 PAMAM dendrimers. The PEGylated PAMAM displayed improved entrapment efficiency of the poorly water-soluble anticancer agent 5-fluorouracil [86]. The effect of PEG chain length on dendrimer-mediated solubility was also studied [87]. Anticancer drugs were encapsulated using a PAMAM dendrimer having MPEG (polyethylene glycol monomethyl ether) grafts of different molecular weights. Two anticancer drugs—methotrexate (MTX) and doxorubicin (DOX) – were encapsulated with high efficiency in the hydrophobic interiors of PEGylated G3 and G4 dendrimers. It was observed that most of the adriamycin was complexed and solubilized on

the surface of mPEG chains, while in the case of MTX, the number of encapsulated molecules increased due to electrostatic interaction resulting from an acid-base reaction between the dendrimer and MTX. With increasing dendrimer generation and PEG molecular weight, more drug molecules can be encapsulated [87]. One way in which dendrimers can assist PEGylation is by increasing the drug loading capacity of PEG polymers, which possess only one or two hydroxyl terminal groups. To overcome this limitation, some research groups have constructed dendrimeric structures at the level of the polymer termini to produce PEG dendrons. The increase in the number of active groups to increase loading capacity is achieved by using branching molecules (e.g., bicarboxylic amino acid) [24,88].

6.2 PEGylated liposomes and Stealth® technology

Liposomes are an important drug delivery technology with many approved injectable products [89-93]. Conventional liposomal formulations suffered from extensive uptake by the reticulo-endothelial system (RES), which is comprised largely of Kupffer cells in the liver and, to a lesser extent, the bone marrow and lymphatic tissue [94-96]. Liposomes were improved by Johnson & Johnson's (USA) Stealth® technology [97], which is composed of lipid nanoparticles that incorporate a PEG coating on the liposome surface, which attracts a water shell to surround the liposome. This shell succeeds in reducing the adsorption of opsonins to the liposome surface that would otherwise enhance recognition and uptake by the RES. The 100 nm diameter size of Stealth® liposomes balances the drug-carrying capacity and circulation time, and also permits extravasation through endothelial gaps in the capillary bed of target tumors [98-101]. Kaposi's sarcoma tumors, in particular, have an inherently leaky capillary bed due to the open-ended or highly permeable vessels that occur during tumor angiogenesis [102].

Paclitaxel (Taxol®) is used for treatment for ovarian carcinoma, breast cancer, head and neck cancers and non-small cell lung cancer [103,104]. However, one of the biggest shortcomings of this drug is its low aqueous solubility. PEGylated liposomes significantly increased the biological half-life of paclitaxel after intravenous injection in rats, and showed a high accumulation of the drug in tumor tissue, thereby more effectively inhibiting the tumor growth in mice. Therefore, this PEGylated liposomal formulation of paclitaxel was suggested to be a better alternative to passive targeting of breast tumors. Similarly, Doxil® (Ortho Biotech L.P. Johnson & Johnson, USA) is a long-circulating Stealth® PEGylated liposomal formulation of doxorubicin.

7. siRNA delivery and PEG

The potential of siRNA as a therapeutic agent in the treatment of chronic diseases and genetic disorders is set for major breakthroughs [105]. However, its delivery, especially via systemic routes, remains a challenge.

Cells do not readily take up siRNA and therefore clinical applications of siRNA largely depend on the development of delivery systems that can bring intact siRNA into the cytoplasm of the target cells. Gene delivery systems should be designed to protect the genetic materials from premature degradation in systemic bloodstream and to efficiently transfer the therapeutic genes to target cells. The PEGylation of these delivery systems protects the siRNA, but other problems can occur such as reduction in gene transfer due to a reduced cellular uptake or limited endosomal release [106].

Polycationic materials can protect nucleic acids from degradation and facilitate entry into the target cells, however, unspecific interactions of the cationic complex can occur with negatively charged serum proteins and other blood components. By PEGylating the polycation, these undesirable effects can be greatly reduced. While PEGylation is a necessity to improve extracellular stability and circulation half-life, it often decreases the transfection efficiency due to reduced specificity and inhibiting cell association and uptake. Furthermore, PEGylation can hinder endosomal release and hence lessen the efficiency at a later phase of the entry pathway. To circumvent this, a pH-cleavable PEG shielding was specifically designed to strip the protective shielding during endosomal uptake [107].

Similarly, Vandenbroucke *et al.* [108] PEGylated siRNA–liposome complexes to prevent aggregation with serum proteins and to prolong circulation time. Ultrasound combined with microbubbles has been used to deliver siRNA, but the gene silencing efficiency is rather low and very high amounts of siRNA are required. To overcome the negative effects of PEGylation and to enhance the efficiency of ultrasound-assisted siRNA delivery, PEGylated siRNA–liposome complexes were attached to the microbubbles. Ultrasound radiation of these microbubbles resulted in an improved intracellular release of unaltered PEG–siRNA–liposome complex. The PEG–siRNA–liposome loaded on microbubbles was able to enter cells after exposure to ultrasound and they induced much higher gene silencing than free PEG–siRNA–liposome. Additionally, the microbubble complex silenced the expression of genes only in the presence of ultrasound, which may enable space- and time-controlled gene silencing.

8. Conclusion

PEGylation has developed substantially over the past decade from an injectable biocompatible technology that was quite generic to one in which many key parameters can be tightly controlled and tailored for each molecule. Current research is exploring ways to use PEG advantageously for oral and inhaled peptide delivery, either in co-polymer or nanoparticle constructs. Combining PEG with other polymeric formats is also showing tremendous promise as it takes advantage of the inherent properties of PEG in providing protection against metabolism and the immune system.

9. Expert opinion

PEGylation is already a mainstay of nanoparticulate formulation and there is considerable research going into combining PEG with chitosan, poly(lactide) co-glycolide (PLG), liposome and dendrimers. Apart from the obvious pharmacokinetic advantages, researchers are likely to achieve better targeting to tissue for diagnostic and treatments, for example, by conjugating ligands to PEG-coated particles. In relation to pulmonary delivery, it is likely that PEGylation will continue to be used to improve the pharmacokinetics of peptides, delivered as non-adherent aerosol particles to the lung. However, the potential for local toxicity from chronic administration cannot be underestimated. Likewise, while PEG is biocompatible, it is not biodegradable (in the same way as PLG) and careful toxicology studies from the newer comb-shaped and co-polymer constructs will be required, with a focus on the potential for build up in the kidneys. Finally, we see great potential for targeted PEGylated polymers as an alternative to live vectors in the delivery of siRNA to the cytosol of cancer cells. To achieve these aims will require ever increased collaboration between chemists, formulators and biologists.

Acknowledgments

We are grateful to Science Foundation Ireland (Investigator Grant 04 IN3 B575 to DB) for funding for the PEGylated sCT work and to Warwick Effect Polymers Ltd. for providing polymer conjugates.

Bibliography

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

1. Beck A, Klinguer-Hamour C, Bussat MC, et al. Peptides as tools and drugs for immunotherapies. *J Pept Sci* 2007;13:588-602
2. Malik DK, Baboota S, Ahuja A, et al. Recent advances in protein and peptide drug delivery systems. *Curr Drug Deliv* 2007;4:141-51
3. Syed S, Schuyler PD, Kulczycky M, et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. *Blood* 1997;89:3243-52
4. Prego C, Torres D, Fernandez-Megia E, et al. Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. *J Control Rel* 2006;11:299-308
5. Schmidt PG, Campbell KM, Hinds KD, et al. PEGylated bioactive molecules in biodegradable polymer microparticles. *Expert Opin Biol Ther* 2007;7:1427-36
6. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. *Drug Discov Today* 2005;10:1451-8
- **Very accessible review for those entering the field.**
7. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. *J Biol Chem* 1977;252:3582-6
8. Abuchowski A, van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. *J Biol Chem* 1977;252:3578-81
- **The first paper showing that a protein could be attached to PEG.**
9. Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. *Adv Drug Deliv Rev* 1995;16:157-82
10. Fee CJ. Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules. *Biotechnol Bioeng* 2007;98:725-31
11. Fung WJ, Porter JE, Bailon P. Strategies for the preparation and characterization of polyethylene glycol (PEG) conjugated pharmaceutical proteins. *Polym Preprints* 1997;38:565-6
12. Youn YS, Jung JY, Oh SH, et al. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. *J Control Rel* 2006;114:334-42
- **Important paper illustrating the potential of site-specific attachment of PEG to a molecule that has great potential to be delivered orally, but one which is normally broken down and has poor permeability.**
13. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. *Bioconjug Chem* 2000;12:195-202
14. Chang LC, Lee HF, Chung MJ, Yang VC. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation. *Bioconjug Chem* 2005;16:147-55
15. Gregoriadis G, Jain S, Papaioannou I, et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. *Int J Pharm* 2005;300:125-30
16. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. *Adv Drug Deliv Rev* 2002;54:459-76
17. Bailey FE, Koleske JV. Poly(Ethylene Oxide). New York: Academic Press; 1976
18. Rabkin R, Dahl DC. Biological Barriers in Protein Delivery: Plenum Press, New York; 1993
19. Webster R, Didier E, Harris P, et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. *Drug Metab Dispos* 2007;35:9-16
20. Modi MW, Fulton JS, Buchmann DK, et al. Clearance of PEGylated (40 kDa) interferon alfa-2a (Pegasy®) is primarily hepatic. *Hepatology* 2000;32:371A
21. Pasut G, Veronese FM. Polymer drug conjugation, recent achievements and general strategies. *Prog Polym Sci* 2007;32:933-61
22. Pasut AG, Veronese FM. Protein, peptide and non-peptide drug PEGylation for therapeutic application. *Expert Opin Ther Patents* 2004;14:859-94
23. Herman S, Hooftman G, Schacht E. Poly(ethylene glycol) with reactive end groups: I Modification of proteins. *J Bioact Biocomp Polymer* 1995;10:145-87
24. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. *Biomaterials* 2001;22:405-17
25. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. *Adv Drug Deliv Rev* 2003;55:1261-77
26. Fishburn CS. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. *J Pharm Sci* 2008; published online 15 Jan 2008, doi:10.1002/jps.21278
27. Helmlinger G, Yuan F, Dellian M, et al. Interstitial pH and pO₂ gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nat Med* 1997;3:177-82
28. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. *Cancer Res* 1989;49:4373-84
29. Zalipsky S, Seltzer R, Menon-Rudolph S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. *Biotech App Biochem* 1992;15:100-14
30. Bentley MD, Roberts MJ, Harris JM. Reductive amination using poly(ethylene glycol) acetaldehyde hydrate generated in situ: applications to chitosan and lysozyme. *J Pharm Sci* 1998;87:1446-9
31. Bentley MD, Harris JM, Kozlowski A. Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation. *PCT US99/23536* (1999)
32. Crawford J. Once-per-cycle pegfilgrastim (Neulasta®) for the management of chemotherapy-induced neutropenia. *Semin Oncol* 2003;4:24-30
33. Pedder SC. Pegylation of interferon alfa: structural and pharmacokinetic properties. *Semin Liver Dis* 2003;23:19-22
34. Brocchini S, Godwin A, Balan S, et al. Disulfide bridge based PEGylation of proteins. *Adv Drug Deliv Rev* 2008;60:3-12
- **A new method addressing site-specific protein PEGylation to avoid loss of biological activity.**
35. Brocchini S, Balan S, Godwin A, et al. PEGylation of native disulfide bonds in proteins. *Nat Protocols* 2006;1:2241-52
36. Balan S, Choi JW, Godwin A, et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. *Bioconjug Chem* 2007;18:61-76

37. Shaunak S, Godwin A, Choi JW, et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. *Nat Chem Biol* 2006;2:312-3
38. Li XQ, Lei JD, Su ZG, et al. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. *Process Biochem* 2007;42:1625-31
39. Krinner EM, Hepp J, Hoffmann P, et al. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. *Protein Eng Des Sel* 2006;19:461-70
40. Zhao H, Yang K, Martinez A, et al. Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. *Bioconjug Chem* 2006;17:341-51
41. Talpaz M, Rakhit A, Rittweger K, et al. Phase I evaluation of a 40-kDa branched-chain long-acting PEGylated IFN-alpha -2a with and without cytarabine in patients with chronic myelogenous leukemia. *Clin Cancer Res* 2005;11:6247-55
42. Schiavon O, Caliceti P, Ferruti P, et al. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). *Farmaco* 2000;55:264-9
43. Lecolley F, Tao L, Mantovani G, et al. A new approach to bioconjugates for proteins and peptides ("pegylation") utilizing living radical polymerisation. *Chem Commun* 2004;18:2026-7
44. Kamigaito M, Ando T, Sawamoto M. Metal-catalyzed living radical polymerization. *Chem Rev* 2001;101:3689-746
45. Tao L, Mantovani G, Lecolley F, et al. Alpha-aldehyde terminally functional methacrylic polymers from living radical polymerization: application in protein conjugation "pegylation". *J Am Chem Soc* 2004;126:13220-1
46. Mantovani G, Lecolley F, Tao L, et al. Design and synthesis of N-maleimido-functionalized hydrophilic polymers via copper-mediated living radical polymerization: a suitable alternative to PEGylation chemistry. *J Am Chem Soc* 2005;127:2966-73
47. Asayama S, Nogawa M, Takei Y, et al. Synthesis of novel polyampholyte comb-type copolymers consisting of a poly(L-lysine) backbone and hyaluronic acid side chains for a DNA carrier. *Bioconjug Chem* 1998;9:476-81
48. Filpula D, Zhao H. Releasable PEGylation of proteins with customized linkers. *Adv Drug Deliv Rev* 2008;60:29-49
49. Asayama S, Maruyama A, Cho CS, Akaike T. Design of comb-type polyamine copolymers for a novel pH-sensitive DNA carrier. *Bioconjug Chem* 1997;8:833-8
50. Srividhya M, Preethi S, Gnanamani A, Reddy BS. Sustained release of protein from poly(ethylene glycol) incorporated amphiphilic comb like polymers. *Int J Pharm* 2006;326:119-27
51. Heredia KL, Bontempo D, Ly T, et al. In situ preparation of protein-"Smart" polymer conjugates with retention of bioactivity. *J Am Chem Soc* 2005;127:16955-60
52. Bontempo D, Maynard HD. Streptavidin as a macroinitiator for polymerization: in situ protein-polymer conjugate formation. *J Am Chem Soc* 2005;127:6508-9
53. Le Droumaguet B, Mantovani G, Haddleton DM, et al. Formation of giant amphiphiles by post-functionalization of hydrophilic protein-polymer conjugates. *J Mater Chem* 2007;19:1916-22
54. Rang HP. Drug discovery and development. Elsevier 2006
55. Read ML, Logan A, Seymour LW. Barriers to gene delivery using synthetic vectors. *Adv Genet* 2005;53:19-46
56. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. *Nat Rev* 2007;6:67-74
- **Excellent forward-looking review written from the physiological perspective by two pioneers of pulmonary delivery of peptides.**
57. Mack GS. Pfizer dumps Exubera. *Nat Biotech* 2007;25:1331-2
58. Muchmore DB, Silverman B, De La Pena A, et al. The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. *Diabetes Technol Ther* 2007;9:S41-7
59. Rosenstock J, Muchmore D, Swanson D, et al. AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. *Expert Rev Med Devices* 2007;4:683-92
60. Odegard PS, Capoccia KL. Inhaled insulin: exubera. *Ann Pharmacother* 2005;39:843-53
61. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. *Clin Pharmacokinet* 2004;43:781-801
62. Barrett R. Post exubera: can new life be breathed back into inhaled insulin? *Drug Deliv Rep* 2008;19-21
63. Leach CL. Modifying the pulmonary absorption and retention of proteins through PEGylation. *Respir Drug Deliv* 2004;9:69-78
64. Niven RW, Whitcomb KL, Shaner L, et al. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. *Pharm Res* 1995;12:1343-9
65. Garcia-Contreras L, Morcol T, Bell SJ, et al. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. *AAPS Pharm Sci* 2003;5:E9
66. Anabousi S, Kleemann E, Bakowsky U, et al. Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. *J Nanosci Nanotech* 2006;6:3010-6
67. Anabousi S, Bakowsky U, Schneider M, et al. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. *Eur J Pharm Sci* 2006;29:367-74
68. Lee YH, Sinko PJ. Oral delivery of salmon calcitonin. *Adv Drug Deliv Rev* 2000;42:225-38
69. Lee WA, Ennis RD, Longenecker JP, et al. The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. *Pharm Res* 1994;11:747-50
70. McHorney CA, Schousboe JT, Cline RR, et al. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. *Curr Med Res Opin* 2007;12:3137-52
71. Youn YS, Na DH, Lee KC. High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation. *J Control Rel* 2007;117:371-9

72. Nicolas J, San Miguel V, Mantovani G, et al. Fluorescently tagged polymer bioconjugates from protein derived macroinitiators. *Chem Commun (Camb)* 2006;45:4697-9
73. Tomalia DA. A new class of polymers: starburst dendritic macromolecules. *Polym J* 1985;17:117-32
74. Tomalia DA, Esfand R. Dendrons, dendrimers and dendrigrafts. *Chem Ind* 1997;11:416-20
75. Svenson S, Tomalia DA. Dendrimers in biomedical applications, reflections on the field. *Adv Drug Deliv Rev* 2005;57:2106-29
76. Yang H, Lopina ST. Stealth dendrimers for antiarrhythmic quinidine delivery. *J Mater Sci Mater Med* 2007;18:2061-5
77. Kobayashi H, Kawamoto S, Jo SK, et al. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. *Bioconjug Chem* 2003;14:388-94
78. Chaltin P, Margineanu A, Marchand D, et al. Delivery of antisense oligonucleotides using cholesterol-modified sense dendrimers and cationic lipids. *Bioconjug Chem* 2005;16:827-36
79. Juliano RL. Intracellular delivery of oligonucleotide conjugates and dendrimer complexes. *Ann NY Acad Sci* 2006;1082:18-26
80. Kang H, DeLong R, Fisher MH, et al. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. *Pharm Res* 2005;22:2099-106
81. Fu HL, Cheng SX, Zhang XZ, et al. Dendrimer/DNA complexes encapsulated in a water soluble polymer and supported on fast degrading star poly(DL-lactide) for localized gene delivery. *J Control Rel* 2007;124:181-8
82. Huang RQ, Qu YH, Ke WL, et al. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. *FASEB J* 2007;21:1117-25
83. Zhong H, He ZG, Li Z, et al. Studies on polyamidoamine dendrimers as efficient gene delivery vector. *J Biomater Appl* 2007; published on 10 July 2007, doi:10.1177/0885328207080005
84. Kolhatkar RB, Kitchens KM, Swaan PW, et al. Surface Acetylation of Polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. *Bioconjug Chem* 2007;18:2054-60
85. Najlah M, Freeman S, Attwood D, et al. In vitro evaluation of dendrimer prodrugs for oral drug delivery. *Int J Pharm* 2007;336:183-90
86. Bhadra D, Bhadra S, Jain S, et al. A PEGylated dendritic nanoparticulate carrier of fluorouracil. *Int J Pharm* 2003;257:111-24
87. Kojima C, Kono K, Maruyama K, et al. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. *Bioconjug Chem* 2000;11:910-7
88. Paleos CM, Tsiourvas D, Sideratou Z. Molecular engineering of dendritic polymers and their application as drug and gene delivery systems. *Mol Pharm* 2007;4:169-88
89. Borm PJ, Muller-Schulte D. Nanoparticles in drug delivery and environmental exposure: same size, same risks? *Nanomedicine* 2006;1:235-49
90. Elsayed MM, Abdallah OY, Naggar VF, et al. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. *Int J Pharm* 2007;332:1-16
91. Kazakov S, Levon K. Liposome-nanogel structures for future pharmaceutical applications. *Curr Pharm Design* 2006;12:4713-28
92. Minko T, Pakunlu RI, Wang Y, et al. New generation of liposomal drugs for cancer. *Anti Cancer Agents Med Chem* 2006;6:537-52
93. Nahar M, Dutta T, Murugesan S, et al. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. *Crit Rev Ther Drug Carrier Syst* 2006;23:259-318
94. Huang A, Kennel SJ, Huang L. Interactions of immunoliposomes with target cells. *J Biol Chemistry* 1983;258:14034-40
95. Straubinger RM, Hong K, Friend DS, et al. Endocytosis of liposomes and intracellular fate of encapsulated molecules: encounter with a low pH compartment after internalization in coated vesicles. *Cell* 1983;32:1069-79
96. Dijkstra J, Van Galen M, Scherphof GL. Effects of ammonium chloride and chloroquine on endocytic uptake of liposomes by Kupffer cells in vitro. *Biochimica et Biophysica Acta* 1984;804:58-67
97. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. *J Clin Oncol* 1999;17:3512-21
98. Colbern GT, Dykes DJ, Engbers C, et al. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. *Clin Cancer Res* 1998;4:3077-82
99. Hatakeyama H, Akita H, Ishida E, et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. *Int J Pharm* 2007;342:194-200
100. Han HD, Lee A, Hwang T, et al. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. *J Control Rel* 2007;120:161-8
101. Lasic D, Martin F. *Stealth Liposomes (Pharmacology and Toxicology Series)*. CRC Press Boca Raton FL 1995
102. Douglas JL, Gustin JK, Dezube B, et al. Kaposi's sarcoma: a model of both malignancy and chronic inflammation. *Panminerva Med* 2007;49:119-38
103. Rowinsky EK, Donehower RC. Paclitaxel (taxol). *N Eng J Med* 1995;332:1004-14
104. Rowinsky EK, Wright M, Monsarrat B, et al. Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. *Ann Oncol* 1994;5:S7-16
105. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. *Adv Drug Deliv Rev* 2007;59:75-86
106. Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. *J Control Rel* 2006;116:255-64
107. DeRouchey J, Schmidt C, Walker GF, et al. Monomolecular Assembly of siRNA and Poly(ethylene glycol)-Peptide Copolymers. *Biomacromolecules* 2008;9:724-32
108. Vandenbroucke RE, Lentacker I, Demeester J, et al. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles. *J Control Rel* 2007; published online 14 Dec 2007, doi:10.1016

109. Graham ML. Pegaspargase: a review of clinical studies. *Adv Drug Deliv Rev* 2003;55:1293-302
110. Chakravarti VS, Borns P, Lobell J, et al. Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID). *Pediatr Radiol* 1991;21:447-8
111. Goffin V, Touraine P. Pegvisomant Pfizer/Sensus. *Curr Opin Investig Drugs* 2004;5:463-8
112. Regehrly M, Greish K, Rancan F, et al. Water-soluble polymer conjugates of ZnPP for photodynamic tumor therapy. *Bioconjug Chem* 2007;18:494-9
113. Greenwald RB, Zhao H, Xia J, et al. Poly(ethylene glycol) prodrugs of the CDK inhibitor, alsterpaullone (NSC 705701): synthesis and pharmacokinetic studies. *Bioconjug Chem* 2004;15:1076-83
114. Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). *Semin Liver Dis* 2004;24:33-8
115. Bukowski RM, Tendler C, Cutler D, et al. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. *Cancer* 2002;95:389-96
116. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). *Curr Pharm Des* 2004;10:1235-44
117. Moshfeghi AA, Puliafito CA. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. *Expert Opin Invest Drugs* 2005;14:671-82

Affiliation

Sin  ad M Ryan¹, Giuseppe Mantovani², Xuexuan Wang³, David M Haddleton⁴ & David J Brayden^{†5}

[†]Author for correspondence

¹Postdoctoral researcher
University College Dublin,
School of Agriculture,
Food Science and Veterinary Medicine,
Veterinary Sciences Building, Room 214,
Belfield, Dublin 4, Ireland

²Postdoctoral researcher,
University of Warwick
Department of Chemistry,
Coventry, UK

³PhD candidate
University College Dublin,
School of Agriculture,
Food Science and Veterinary Medicine,
Belfield, Dublin 4, Ireland

⁴Professor of Chemistry
University of Warwick,
Department of Chemistry,
Coventry, UK

⁵Professor of Drug Delivery
University College Dublin,
School of Agriculture,
Food Science and Veterinary Medicine,
Belfield, Dublin 4, Ireland
Tel: +353 1 7166013; Fax: +353 1 7166019;
E-mail: David.Brayden@ucd.ie